Browse NANOG

Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00046 Homeobox domain
Function

Transcription regulator involved in inner cell mass and embryonic stem (ES) cells proliferation and self-renewal. Imposes pluripotency on ES cells and prevents their differentiation towards extraembryonic endoderm and trophectoderm lineages. Blocks bone morphogenetic protein-induced mesoderm differentiation of ES cells by physically interacting with SMAD1 and interfering with the recruitment of coactivators to the active SMAD transcriptional complexes. Acts as a transcriptional activator or repressor. Binds optimally to the DNA consensus sequence 5'-TAAT[GT][GT]-3' or 5'-[CG][GA][CG]C[GC]ATTAN[GC]-3'. Binds to the POU5F1/OCT4 promoter (PubMed:25825768). Able to autorepress its expression in differentiating (ES) cells: binds to its own promoter following interaction with ZNF281/ZFP281, leading to recruitment of the NuRD complex and subsequent repression of expression. When overexpressed, promotes cells to enter into S phase and proliferation.

> Gene Ontology
 
Biological Process GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001708 cell fate specification
GO:0001711 endodermal cell fate commitment
GO:0001714 endodermal cell fate specification
GO:0007369 gastrulation
GO:0007492 endoderm development
GO:0019827 stem cell population maintenance
GO:0035019 somatic stem cell population maintenance
GO:0035987 endodermal cell differentiation
GO:0045165 cell fate commitment
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0098727 maintenance of cell number
Molecular Function GO:0003714 transcription corepressor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1266738: Developmental Biology
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-449147: Signaling by Interleukins
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NANOG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NANOG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23093782Colon carcinomaInhibit immunityInhibition of Nanog in a murine model of colon cancer rendered tumor cells susceptible to immune-mediated clearance and led to successful, long-term control of the disease.
28716899Squamous Cell CarcinomaInhibit immunity; Resistant to immunotherapyNANOG upregulated HDAC1 through promoter occupancy, thereby decreasing histone H3 acetylation on K14 and K27. Our results reveal that NANOG influences the epigenetic state of tumor cells via HDAC1, and they encourage a rational application of epigenetic modulators and immunotherapy in treatment of NANOG+ refractory cancer types.
24227785MelanomaInhibit immunityWe observed that hypoxia-induced Nanog correlated with the acquisition of stem cell-like properties in B16-F10 cells. Nanog targeting significantly reduced immunosuppressive cells (regulatory T cells and macrophages) and increased CD8(+) T effector cells in tumor bed in part by modulating TGF-β1 production. Additionally, Nanog regulated TGF-β1 under hypoxia by directly binding the TGF-β1 proximal promoter.
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NANOG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NANOG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4080.458
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4270.661
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3880.721
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2030.262
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NANOG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.817.6-12.80.307
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NANOG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NANOG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NANOG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NANOG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NANOG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NANOG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNANOG
NameNanog homeobox
Aliases FLJ12581; FLJ40451; homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; hNano ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NANOG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.